Clinical Trial Update: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 3]

View source ↗

Summary

Phase 3 study of Daraxonrasib (RMC-6236) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Daraxonrasib

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Pancreatic Cancer, PDAC | Phase 3 | Status: ACTIVE_NOT_RECRUITING